NMRA vs CLYM

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 05, 2026

NMRA

36.3
AI Score
VS
CLYM Wins

CLYM

48.5
AI Score

Investment Advisor Scores

NMRA

36score
Recommendation
SELL

CLYM

49score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric NMRA CLYM Winner
Net Income -96.54M -27.22M CLYM
Operating Income -95.05M -30.57M CLYM
ROE -216.9% -11.4% CLYM
ROA -77.1% -11.1% CLYM
Total Assets 125.25M 246.29M CLYM
Cash 116.83M 44.11M NMRA
Current Ratio 4.50 31.45 CLYM
Free Cash Flow -85.95M -25.18M CLYM

Relative Price Performance (Last 90 Days)

NMRA 1M: +6.7% · 3M: -72.7% CLYM 1M: +8.4% · 3M: -18.4%

Current Technical Phase

NMRA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -40.9%), weak momentum, RSI 44

RSI (14): 44.3 · Price: $0.47

CLYM

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 58

RSI (14): 58.3 · Price: $11.74

Fundamentals Snapshot

Metric NMRA CLYM
Market Cap — —
Forward P/E -0.7 -11.7
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin — —
Operating Margin 0.0% 0.0%
EPS -1.20 -0.87
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CLYM is currently the stronger investment candidate, winning 7 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.